Pörssitiedote

Number of Shares and Votes in Nanologica AB (publ)

The number of registered shares and votes in Nanologica AB has changed during the month of November following the registration of parts of the previously communicated rights issue.

The rights issue was subscribed for approximately 87.0 percent with and without the support of unit rights, whereby the underwriting commitment from Flerie Invest AB was used for 1,438,755 units, corresponding to the remaining approximately 13.0 percent of the rights issue. The part of the issue relating to the underwriting commitment was allocated and registered with the Swedish Companies Registration Office in November. This means that during November, the number of shares in Nanologica has increased by 5,755,020 shares from 82,602,214 to 88,357,234 shares and that the share capital has increased by SEK 575,502.0 from SEK 8,260,221.4 to SEK 8,835,723.4.

The Extraordinary General Meeting on September 23, 2024, resolved to reduce the share capital by an amount in SEK corresponding to the amount by which the share capital increases through the rights issue (regarding the part where the share capital increase is attributable to a new issue of shares), with relevant adjustments to achieve an appropriate quota value. During November, Nanologica applied for permission from the Swedish Companies Registration Office for a reduction of the share capital by SEK 4,329,504.466, from SEK 8,835,723.4 to SEK 4,506,218.934. Subject to the Swedish Companies Registration Office’s approval which is expected in January at the earliest, the share’s quota value after the reduction will amount to SEK 0.051 per share.

As of November 29, 2024, the last trading day of the month, the total number of shares and votes in Nanologica AB amounted to 88,357,234.

About Nanologica AB (publ)
Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.